Restricted accessResearch articleFirst published online 2020-2
New insights into antiphospholipid-related endothelial dysfunction by assessment of vascular glycocalyx layer: results from a preliminary cross-sectional study
Antiphospholipid syndrome (APS) is associated with greater atherothrombotic risk and endothelial dysfunction, suggesting that endothelial glycocalyx is impaired in this disease.
Objectives
The aim was to investigate the endothelial glycocalyx and the relationship between glycocalyx markers, endothelial dysfunction parameters and atherosclerotic markers in APS.
Methods
A total of 15 primary arterial APS patients and healthy controls were included in the study. Glycocalyx was assessed in both groups by sublingual sidestream dark field imaging and syndecan-1 plasma level. Endothelial function was evaluated by brachial artery flow-mediated dilatation (FMD) and early atherosclerosis by carotid intima media thickness (IMT). Thrombotic profile was also performed by measuring the plasma level of the tissue factor (TF).
Results
APS patients had significantly increased syndecan-1 plasma level 38.6 ± 5.0 pg/ml vs. 19.1 ± 3.5 pg/ml; p < 0.01 and a reduced glycocalyx thickness 0.26 ± 0.03 µm vs. 0.75 ± 0.07 µm; p < 0.01 compared with control. FMD was impaired in APS patients compared with control, 5.68% ± 0.42 vs. 8.29 ± 0.30, p < 0.01, respectively. IMT was significantly increased in APS patients compared with control, 0.52 ± 0.13 mm vs. 0.40 ± 0.06 mm, p < 0.01, respectively. Soluble TF, thiobarbituric acid-reactive substances levels were increased in the sera from APS patients compared with control.
Conclusions
This preliminary study supports, for the first time, that in APS patients endothelial glycocalyx is impaired, which could lead to thrombosis, endothelial dysfunction and early atherosclerosis.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH2006; 4: 295–306.
2.
RandJHWuXXAndreeHA, et al.Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A ‘lupus procoagulant’ phenomenon. Blood1998; 92: 1652–1660.
3.
KinevAVRoubeyRAS. Tissue factor in the antiphospholipid syndrome. Lupus2008; 17: 952–958.
4.
ErkanDYaziciYPetersonMGSammaritanoLLockshinMD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatol Oxf Engl2002; 41: 924–929.
5.
DrexlerHHornigB. Endothelial dysfunction in human disease. J Mol Cell Cardiol1999; 31: 51–60.
6.
BenhamouYBellienJArmengolG, et al.Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol2014; 66: 3210–3220.
7.
CharakidaMBeslerCBatucaJR, et al.Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA J Am Med Assoc2009; 302: 1210–1217.
8.
NobleMIMDrake-HollandAJVinkH. Hypothesis: Arterial glycocalyx dysfunction is the first step in the atherothrombotic process. QJM Mon J Assoc Physicians2008; 101: 513–518.
9.
PadbergJ-SWiesingerAdi MarcoGS, et al.Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis2014; 234: 335–343.
10.
ReitsmaSOude EgbrinkMGAHeijnenVVT, et al.Endothelial glycocalyx thickness and platelet-vessel wall interactions during atherogenesis. Thromb Haemost2011; 106: 939–946.
11.
CancelLMEbongEEMensahSHirschbergCTarbellJM. Endothelial glycocalyx, apoptosis and inflammation in an atherosclerotic mouse model. Atherosclerosis2016; 252: 136–146.
12.
BergBM van denSpaanJAERolfTMVinkH. Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am J Physiol - Heart Circ Physiol2006; 290: H915–H920.
13.
Rubio-GayossoIPlattsSHDulingBR. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol2006; 290: H2247–2256.
14.
López-Pedrera C, Barbarroja N, Jimenez-Gomez Y, et al. Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. Rheumatology (Oxford) 2016; 55: 2096–2108.
15.
Müller-CallejaNHollerbachAHäuserFCanisiusAOrningCLackerKJ. Antiphospholipid antibody-induced cellular responses depend on epitope specificity: Implications for treatment of antiphospholipid syndrome. J Thromb Haemost2017; 15: 2367–2376.
16.
NadirYBrennerBFuxLShafatIAttiasJVlodavskyI. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica2010; 95: 1927–1927.
17.
BakerABGibsonWJKolachalamaVB, et al.Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J Am Coll Cardiol2012; 59: 1551–1560.
18.
GoodallKJPoonIKHPhippsSHulettMD. Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS ONE. 9. Epub ahead of print 8 October 2014. DOI: 10.1371/journal.pone.0109596.
19.
BlichMGolanAArvatzG, et al.Macrophages activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol2013; 33: e56–e56.
20.
PengoVTripodiAReberG, et al.Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost JTH2009; 7: 1737–1740.
21.
MirandaSArmengolGLe BesneraisMLévesqueHBenhamouY. New insights into systemic sclerosis related microcirculatory dysfunction by assessment of sublingual microcirculation and vascular glycocalyx layer. Results from a preliminary study. Microvasc Res2015; 99: 72–77.
22.
NieuwdorpMMeuweseMCMooijHL, et al.Measuring endothelial glycocalyx dimensions in humans: A potential novel tool to monitor vascular vulnerability. J Appl Physiol Bethesda Md 19852008; 104: 845–852.
23.
LiuhanenSSallisalmiMPettiläVOksalaNTenhunenJ. Indirect measurement of the vascular endothelial glycocalyx layer thickness in human submucosal capillaries with a plug-in for ImageJ. Comput Methods Programs Biomed2013; 110: 38–47.
24.
MalteteDBellienJCabrejoL, et al.Hypertrophic remodeling and increased arterial stiffness in patients with intracranial aneurysms. Atherosclerosis2010; 211: 486–491.
25.
BellienJIacobMRemy-JouetI, et al.Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. Circulation2012; 125: 1266–1275.
26.
NieuwdorpMvan HaeftenTWGouverneurMCLG, et al.Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes2006; 55: 480–486.
27.
MirandaCHde Carvalho BorgesMSchmidtAMarin-NetoJAPazin-FilhoA. Evaluation of the endothelial glycocalyx damage in patients with acute coronary syndrome. Atherosclerosis2016; 247: 184–188.
28.
JohanssonPIStensballeJRasmussenLSOstrowskiSR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg2011; 254: 194–200.
29.
KimKJKimJYBaekIWKimWUChoCS. Elevated serum levels of syndecan-1 are associated with renal involvement in patients with systemic lupus erythematosus. J Rheumatol2015; 42: 202–209.
30.
EbongEELopez-QuinteroSVRizzoVSprayDCTarbellJM. Shear-induced endothelial NOS activation and remodeling via heparan sulfate, glypican-1, and syndecan-1. Integr Biol2014; 6: 338–347.
31.
VoyvodicPLMinDLiuR, et al.Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. J Biol Chem2014; 289: 9547–9559.
32.
MochizukiSVinkHHiramatsuO, et al.Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am J Physiol Heart Circ Physiol2003; 285: H722–726.
33.
NieuwdorpMHollemanF. Groot E de, et al. Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. Diabetologia2007; 50: 1288–1293.
34.
PahwaRNallasamyPJialalI. Toll-like receptors 2 and 4 mediate hyperglycemia induced macrovascular aortic endothelial cell inflammation and perturbation of the endothelial glycocalyx. J Diabetes Complications2016; 30: 563–572.
35.
BenhamouYMirandaSArmengolG, et al.Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: Role of reduced oxidative stress. Vascul Pharmacol2015; 71: 93–101.
36.
MirandaSBilloirPDamianL, et al.Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. PloS One2019; 14: e0212614–e0212614.
37.
SoriceMLongoACapozziA, et al.Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum2007; 56: 2687–2697.
38.
PrinzNClemensNCanisiusALacknerKJ. Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome. Thromb Haemost2013; 109: 525–531.
39.
SchmidtEPYangYJanssenWJ, et al.The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med2012; 18: 1217–1223.
